{
  "doc_id": "IPT_50-2022-Tecentriq",
  "chunks": [
    {
      "text": "POSITIONING REPORT THERAPE PT/V1/50/2022 Positioning report Ter (Tecentriq®) in combination with hepatocellular carcinoma Date of publication: 07 June 2022 INTRODUCTION Hepatocellulose Carcinoma (HCC) is considered one of the most important causes of morbidity and mortality worldwide, drastically influencing the life expectancy of patients. According to the latest available data, globally, HCC ranks seventh in incidence and fourth in direct mortality from cancer (1).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 0
      }
    },
    {
      "text": "The incidence of HCC increases with age (exceptionally it occurs before 40 years and the median age at diagnosis in our midst is between 65-70 years), being more frequent in men than in women (2). The rate of incidence is higher in western and south-eastern Africa, where the main etiological factors are hepatitis B and Hepatitis B Virus (HBV) infection. According to the latest data from the Spanish Society of Medical Oncology (SEOM), from January to May 2020, 2,075 people died from malignant tumors of the liver and intrahepatic bile ducts; and an incidence of 1,551 new cases of CHC is estimated for 2021 (6). In Europe, Oceania and America, the main etiological factors are chronic infection by the Hepatitis C Virus (HCV) and alcohol consumption, adding in the last decade, fatty liver associated with metabolic disease (MAFLD, from the English metabolic dysfunction associated fatty Liver disease) (3-5).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "The Barcelona Clinic Liver Cancer (BCLC) system continues to be the one recommended by the vast majority of clinical guidelines (8-10). This system establishes the prognosis according to five stages and in turn correlates it with some therapeutic options. Stages BCLC 0 or very early (includes patients with compensated cirrhosis [Child-Pugh A], asymptomatic (performance status (PS) 0), who present single tumors < 2 cm without vascular invasion or dissemination) and BCLC A or early (include asymtomatic (PS 0) patients with conserved solitary hepatic function [child-pugh A and B] with a CHC or a maximum of 3 nodules ≤ 3 cm), are candidates for intentional treatments (tumor resection, hepatic transplantation or percutaneous ablation),",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "2_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "with survival rates ranging from around 60% to 80% at 5 years. In stage B or intermediate (includes patients with multinodular tumours that do not meet the criteria described above, without vascular or extrahepatic invasion, with preserved hepatic function and general condition) transarterial chemoembolization is the main treatment option. Stage D or terminal BCLC includes patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc. They are characterised by deterioration of general condition and/or severely impaired hepatic function with median survival not exceeding four months and where the only therapeutic option is best supportive care (8-10 years).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "2_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "First, sorafenib (Nexavar®) was incorporated as a systemic treatment for HCC following three pivotal Phase III studies. In 2006, study 100554 was conducted where overall survival (OS) with soravenib was 46.3 vs. 34.4 weeks with placebo, with a hazard ratio (HR) of 0.69 (95% confidence interval (CI) 0.55-0.86, p 0.0006) (11). In 2008 the SHARP study was published in which Sorafenib achieved OS of 10.7 vs. 7.9 months in patients treated with placebo with an OS of 0. 69 (95% CI of 0.55-10.87, p < 0.001) (12). Similarly, in 2009 the study NCT00492 (Asia-Pacific) was published where SG with sorafenub was 6.5 vs. 4.2 months",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "3_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "with placebo and 95% HR of 0.68 (CI of 0.93-0.014) remained as the only alternative to CHC for three years after these trials. Following these three trials, sorafenib remained for years as the only alternative in the systemic treatment of HCC. In 2018, in the phase III and non-inferiority REFLECT trial, lenvatinib (Lenvima®) achieved an OS of 13.6 months compared to 12.3 with soraphenib. After marking the limits of non inferiority and superiority, the results showed that levantinib was not inferior to sorafenab. Only differences in adverse effects were established between Sorafenib and lenvatanib, in grade 3-4 hypertension (14% vs. 23%) and hand-foot syndrome (11% vs.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "3_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "3%) (14). Finally, in 2020, the combination of this IPT, atezolizumab and bevacib, after the phase II clinical trial of IMIIvebra150 has been authorized for the treatment of advanced or untreatable first-line CHC (see Annex 1). This review will be discussed in Table 1 of this document (15). The combination of atezolizumab with bevacizumab is indicated in advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy. This combination was approved by the Food and Drug Administration (FDA) in May 2020 and by the",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "4_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "European Medicines Agency (EMA) in October 2020 (16, 17). Another authorised indication of the combination of Atezolizumab and bevazizumab together with paclitaxel and carboplatin is the first-line treatment of non-metastatic non-squamous metastatic microcytic lung cancer (NMSC) in adult patients whose tumours do not express alterations in EGFRK or ALK, which is not the target of this ATT (ATEZUZumab) intravenous perfume solution at a recommended dose of 1,200 mg Atezolidumab (18) administered intravenously every three weeks. The recommended dose is 1,200 mg given intravenously as a slow infusion every three weeks.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "4_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "The initial dose of atezolizumab should be administered for 60 minutes. If the first infusion is well tolerated, subsequent infusions may be given for 30 minutes. It is recommended that patients be treated until loss of clinical benefit or onset of unmanageable toxicity. Pharmacology Atezolizumab is a genetically engineered humanised IgG1 Fc monoclonal antibody, an anti-ligand of the PDL1 programmed death ligand receptor, produced in Chinese hamster ovary cells by recombinant technology. Efficacy and safety have not been studied in the population below 18 years of age.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 5
      }
    },
    {
      "text": "No dose adjustment is necessary in patients ≥ 65 years. Safety-effectiveness has not been investigated in patients with renal insufficiency or patients with hepatic impairment. It is recommended that patients be treated until loss of clinical benefit or onset of unacceptable toxicity. Efficacy The efficacy data for the combination of atezolizumab plus bevacizumab are derived from the GO30140 trial (Phase IB) which demonstrated an additive effect of bevazizumab with respect to atezoizumab monotherapy in patients with unresectable CHC, and from the IMbrave 150 trial (phase III) (15, 20). A multicentre and multinational, parallel-group study comparing the combination of atezolizumab plus bevacizumab versus sorafenib.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 6
      }
    },
    {
      "text": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients were included. Stratification was performed by geographical region (Asia [excluding Japan] vs. rest of the world), macrovascular invasion and/ or extrahepatic dissemination (presence vs. absence), baseline alpha-fetoprotein (AFP) levels (ng< 400m/ L vs. ≥ 400 m/ L) and overall status (0 ECOG vs.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 7
      }
    },
    {
      "text": "group 1). Patients randomised to the sorafenib group received 400 mg of the drug, orally, twice daily. Treatment continued until unacceptable toxicity or loss of benefit. Therapy could be continued beyond progression if there was evidence of clinical benefit at the discretion of the investigator. No dose adjustments were allowed in the atezolizumab-bevacizumab arm, but were permitted in the Sorafenib arm. Tumor assessments were performed every 6 weeks for one year and subsequently every 9 weeks. The targets of the study were, as primary targets, overall survival (OS) (time from randomisation to death from any cause) and progression-free survivorship (PFS) (Time from randomization to",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "8_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "tumour progression defined by RISTEC 1.1 criteria or death by any cause). The secondary endpoints were the objective response rate (percentage of patients with partial or complete response) following RECIST 1.1 and modified RESIST criteria for liver disease (mRECIST), duration of response (time from partial to complete response to disease progression or exit), and deterioration in patient quality of life (based on the EORTC QLQ-C30 test and the Eortc QLq-HCC18 test). From March 2018 to January 2019, 501 patients from 111 hospitals and 17 countries were included, who were randomly assigned to receive atezobevacizumab (336 patients) or sorafenib (165 patients), based on statistical characteristics.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "8_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "An analysis of progression-free survival (PFS), two intermediate analyses and a final analysis of overall survival were planned. The primary analysis was to be performed after approximately 308 cases of disease progression or death, and the first intermediate analysis of global survival was scheduled to be carried out at the same time. Up to 29 August 2019, a total of 306 case of disease progress or death had occurred, including 161 deaths. Overall survival was significantly higher in the atezolizumab-bevacizumab treatment arm; the median survival rate was 84.8% (95% CI 80.9-88.7) and 67.2% (95% IC 61.3-73.1) at 6 and 12 months, respectively, in the dezolizumab-bavizumab group; and 72.2% (90% CI 65.1-79.4) and 54.6% (95%CI 45.2-64.0) at 6 months and 12 month in the sorafenib group. Overall, the subgroup analyses showed that the results are consistent with the overall estimates of SG and SLP (see Annex, Table 3).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 9
      }
    },
    {
      "text": "With respect to the secondary endpoints, the objective response rate was 27.3% (95% CI 22.5-32.5%) for the atezolizumab-bevacizumab combination and 11.9% (95%CI 7.4-18.0%) for sorafenzumab according to RISTEC criteria 1.1 (p < 0.001) and 33.2% (95% IC 0.47-0.76, p< 0.0001) and 13.3% (IC 28.1-38.6) and 13.5% (IC 8.4-19.6) according to mISTEC criterion 1.00, respectively. In the atezolizumab-bevacizumab group, the median time to quality of life impairment reported by patients was 11.2 months and 3.6 months, respectively (HR 0.63, 95% CI, 0.46-0.85) on the full scale; 13.1 months and 4.9 months, respective (HR 0.53, 95% IC, 0.39-0.73) on the fitness sub-scale; and 9.1 and 3.6, respectively, on the EORTC QLQ-C30 questionnaire (completion of at least one question) from treatment initiation to cycle 17, and 80% from there to treatment discontinuation.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 10
      }
    },
    {
      "text": "The median OS was 19.2 months with atezolizumab + bevacizumab versus 13.4 months with sorafenib (HR, 0.66 [95% CI, 0.52, 0.85]; P = 0.0009). The survival at 18 months was 52% with atezlizimab + Bevacizumab and 40% with Sorafenib. In relation to the safety of the atezolizumab combination, the most frequent adverse reactions overall were: hypertension (29.8%), fatigue (20.4%), proteinuria (20.1%), increased aspartate aminotransferase (19.5%), pruritus (19,5%), diarrhoea (18.8%), fever (17.9%), loss of appetite (17.6%), increased alanine amintransferase (ALT) (14%), constipation (13.4%), increased serum bilirubin (13.1%), abdominal pain (12.5%), nausea (12.2%), cough (11.2%), thromboplastinemia (10.2%), weight loss (11.3%), epilepsy (10.7%),",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "11_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "palmar rash (11.2%) and trombocytopenia (10.3%). The most common grade 3-4 adverse event in the atezolizumab-bevacizumab arm was hypertension (15.2%), a well-established adverse effect in the safety profile of bevazizumab. The most frequent grade 3 or 4 adverse reactions were: hypertension (15.2%), increased aspartate aminotransferase (AST) (7%), increased ALT (3.6%), thrombocytopenia (3.3%), proteinuria (3%), fatigue (2.4%), increased serum bilirubin (2.4%), infusion reaction (2.4%) diarrhoea (1.8%), decreased appetite (1.2%), fever (1.2%), abdominal pain (1.2%) nausea (0.3%) and asthenia (0.3%). Grade 5 adverse effects occurred in 15 patients in the atezolizumab-bevacizumab combination group (4.6%) and in 9 patients of the sorafenib group (5.8%).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "11_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "Serious adverse events were more frequent in the atezolizumab-bevacizumab group (125 patients, 38%) than in the sorafenib group (48 patients, 30.8%), and the main differences were observed in gastrointestinal disorders, including bleeding (14.9% versus 11.5%) and infections (7.3% versus 1.9%). A higher proportion of patients in the atezolizumab-bevacizumab group with liver disorders (43.2% vs 39.7%), hypothyroidism (10.9% vs 2.6%), infusion reactions (10.9%) and hyperthyroidism (4.9% vs 0). at least one event occurred in a higher proportion of patients on atezolizumab-bevacizumab than on sorafenib (57.8% versus 48.7%). Notable were the increased frequency of hypertension (31.0% on atezumab versus 24.6% on soravenib), bleeding (25.2% versus 17.3%) and proteinuria (21.3% versus 8.3%). Diabetes mellitus occurred for 2.0% (10/493) of patients receiving atezoizumab in combination with bevacizumab. The median time to",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "12_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "onset was 4.4 months (range: 1.2-8.3 months). No case of diabetes mellitus led to withdrawal of atezozizumab. No case of diabetes mellitus led to the withdrawal of atezolizumab. The updated analysis with an additional 12 months of follow-up of the IMbrave 150 study showed no new signs of toxicity in the atezolizeumab + bevacizumab group, although the frequency of hypertension increased from 24% to 28% and proteinuria from 19% to 29%, as well as the incidence of immuno-mediated hepatitis (defined by diagnosis and/ or laboratory abnormalities) whose increase of 10% was considered mainly responsible for the increase in the rate of adverse events of special concern from 69% to 76% compared to the primary analysis (21). Dose reductions for any reason were not permitted in the atezolizumab-bevacizumab arm.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "12_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "49.5% of patients in the Atezumab group and 60.9% in the Sorafenib group (41.0% drug withdrawal) had to modify the dose or discontinue the drug due to adverse events (15). The estimated clinical benefit would be 5, considering the HR 0.58 and a difference of 9.6 months in SG from the extrapolation of the KM curves (22). The recently published updated analysis of an additional 12 months of follow-up shows somewhat reduced outcomes (HR 0.66 and difference from medians of 5.9 months), but with that benefit the assessment would be maintained (21). DISCUSSION HCC is one of the most impactful neoplasms in terms of morbimortality despite the availability of a screening targeted at risk population and a well-established diagnostic algorithm (23). See Annex, Figure 2.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 13
      }
    },
    {
      "text": "To date, no biomarkers have been identified that serve as predictors of response to one treatment or another, or that are able to predict longer or shorter survival of patients (24). In recent years there have been advances from the therapeutic point of view with several drug positions in the treatment algorithm. In 2008, in the SHARP study, sorafenib achieved a median SG of 10.7 vs. 7.9 months in placebo-treated patients, with a HR of 0.69 (95% CI 0.55-0.87, p < 0.001) (12). In 2009, the Asia-Pacific study (NCT00492752) was published where the SG with soraphenib was 6.5 months vs. 4.2 with placebo with HR 95% of 0.68 (IC 0.5-0.93, p 0.014) - Lenvatinib (Lenvima®): In 2018, in the REFLECT study, lenvatinib achieved an SG of 13.6 vs. 12.3 months with sorafenub.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 14
      }
    },
    {
      "text": "The results showed that sorafenb was not inferior to linear sorafenab, and after several years of treatment, it was not authorized for use in the CHC regimen. Regarding first-line treatments, for several years sorafenib was the only systemic treatment available for HCC. While the safety profile of sorafenub was acceptable in the context of this disease, the overall prognosis of HCC with this treatment continued to be unsatisfactory. This led to numerous trials to try to obtain new alternatives. In 2018, the REFLECT trial demonstrated non-inferiority of lenvatinib with respect to lenfenib (25). All patients had locally advanced, unresectable or metastatic CHC, for which they had not received prior systemic therapy. Stratification was performed by geographical region (Asia [excluding Japan] vs. rest of the world), macrovascular invasiveness and/ or dissemination (BC), absenteeism vs. absence of athezolizumab-bevacizumab: sorafenib,",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "15_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "open-label, multicentre and international phase III clinical trial comparing a arm of patients treated with the atezolizumab/ bevacizumab combination versus a arm treated with sorapenib. It should be noted that IMbrave150 is the first CHC trial in which a therapeutic option is statistically significantly superior to another treatment compared, rather than to placebo. In both SG and SLP, the combination of sorazumab atevacizumab was superior to affenib. The median survival rate was 84.8% (ICI 95%-80.98) at 6 months and 67.95% (ICIC 61.32) at 12 months; 74.2% at 64, 95% and 72.2% at 12-72 months in the atevazizumab group and 74.1% at 61, 95% at 12-62 months; and 75.2% at 54, 95% at 65, 64, 64, 71, 12 and 12 months. (IC 95% 65.1-79.4) at 6 months and 54.6% at 12 months (95% IC 45.2-64.0) in the sorafenib group.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "15_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "SG data are from the first interim analysis, so were not yet sufficiently mature to definitively quantify clinical benefit, and 161 deaths out of 312 were observed according to the pre-specified SG analyses. The updated objective response rate (ORR; 29.8% according to RECIST 1.1) with atezolizumab + bevacizumab was in line with the primary analysis, with a complete response rate of 8% versus < 1% with sorafenib. The rate of response was 27.3% (95% CI 22.5-32.5%) with the atezolizumabbevacizumab combination and 11.9% (95% IC 7.4-18.0%) with",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "16_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "sorafenib according to RECIST 1.1 (p < 0.001) and 33.2% (95%CI 28.1-38.6%) and 13.3% (955%CI 8.4 19.6%) respectively according to mRECIST (p< 00.1) criteria. In the atezolizumab-bevacizumab group and in the sorafenib group, the median time to patient-reported impairment of quality of life was 11.2 and 3.6 months respectively (HR 0.63, 95% CI, 0.46-0.85) on the full scale; 13.1 and 4.9 months, respectively, (HR 0.53, 95% IC, 0.39-0.73) on the fitness sub-scale; and 9.1 and 3.6, respectively (0,62, 95% CI 0,46-0,84) on the functional role subscale.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "16_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "Serious adverse events were more frequent in the atezolizumab-bevacizumab group (125 patients, 38%) than in the sorafenib group (48 patients, 30.8%). Overall, the adverse reactions observed reflected the known safety profile of Sorafenib, atezumab and bevacizumab. Conclusion The combination of atezolizumab plus bevacizumab has been shown to be superior to sorafenib in an open-label randomised phase III trial (brave IMIM150) in the treatment of patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4. The mean survival rate was 84.8% (95% CI 80.9-88.7%) at 6 months, 67.2% (95% IC 61.3-73.1%) at 12 months, and 52% at 18 months in the atezolizumab-vacizumab group; and 72.2% (955% CI 65.1-79.4%) at six months, 54.6% at twelve months (95%CI 45.2-64.0%), and 40% at 18 month in the sorafenib-free group.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 17
      }
    },
    {
      "text": "Although serious adverse reactions were more frequent in the atezolizumab-bevacizumab group (125 patients, 38%) than in the sorafenib group (48 patients, 30.8%), it should be noted that if we restrict ourselves to grade 5 adverse events, this is not observed: 5.8% with sorafenub vs. 4.6% with atezolizeumab bevacizumab. The combination of atezolizumab and bevacizumab is an option that adds therapeutic value to the treatment of patients with advanced and/ or unresectable hepatocellular carcinoma who have not received prior systemic therapy with superior efficacy and a safety profile distinct from sorafenib in",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "18_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "line with the known profile for atezoizumab or bevazib alone and may present more adverse events. The DGCCSSNSYF has issued a funding resolution for the indication of TECENTRIQ® (atezolizumab) in combination with bevacizumab, in the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy, with hepatic function (Child-Pugh carcinomas: a phase III randomised, double-blind, stage A), an ECOG score of 0 or 1, in the absence of a placebo-controlled trial. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "18_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "Lenvatinib versus sorafenib in first-line REFERENCIAS treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. 1. Siegel, R.L; Miller, K.D; Jemal, A. Cancer statistics, Lancet. 2018;391 (10126): 116373. 2019. CA Cancer A J Clin, 69: 7-34. 15. Finn, RS Qin, S Ikeda M, Galle PR, Ducreux M, Kim 2. Mittal S, El-Serag Sada, HB YH, Kanwal F, Duan Z, TY, and IM; alvebra150 Investigators.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 19
      }
    },
    {
      "text": "Atelizumab S, S and al. Hepatozumab in the absence of fatty liver cancer in addition to the Bevacivable Hepatocell Carcinoma in the United States is associated with cirrhosis of the liver. This is a list of all the different ways Hepatol is credited in the database. See also List of drugs approved by the U.S. Food and Drug Administration (FDA) for treatment of non-alcoholic fatty liver disease. 2016;14:12431.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 20
      }
    },
    {
      "text": "atezolizumab plus bevacizumab for unresectable 3. Gomaa aI, Khan Sa, Toledano MB, Waked I, Taylor-Hepatocellular carnicoma. Worldwide incidence and trends. %20therapy. (accessed May 2021) Gastroenterology 2004; 127 (5 Suppl 1): S5- S16. 17. European Medicines Agency, CHMP extension of GROUP OF EXPERTS (in alphabetical order) Spanish Agency for Medicines and Health Products Nodes in the REvalMed network: Oncology node. Digestive, Renal and Prostate subnode.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 21
      }
    },
    {
      "text": "Raul Andrade. Director of the Clinical Management Unit of the digestive system, University Hospital Virgen de la Victoria. All experts have made a declaration of conflicts of interest. All the experts have made a declaration of conflicts of interest.The Head Laboratory, the Spanish Society of Hospital Pharmacy, the Spaniard Society of Clinical Pharmacology, Spanish Medical Oncology Society, Spanish Association for the Study of the Liver, Spanish Society for Liver Transplant, Spanish society of digestive pathology, the spanish Association of Gastroenterology, The Spanish Patient Forum, the Platform of Patient Organizations, the General Alliance",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "22_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "of Patients, Spanish Group of Cancer Patients and the National Federation of Liver Infected and Transplanted have had the opportunity to send comments to the document, although the final text is the one adopted by the Coordination Group of the REvalMed Table 1. Table 1.Differential characteristics IMbrave comp 150) with other similar alternatives DIFFERENT CHARACTERISTICS Name Atezolizumab-bev Trade name Tecentriq®-Avastin® Intravenous presentation Posology 1200mg-atezolizum 15mg/kg-bevacizum Every three weeks Indication Yes approved in FT or not Adverse effects Arterial hypertension (in order of fatigue frequency) Proteinuria Need for use of medical resources (HDM).",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "22_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "Intrahospital Adm Efficacy (according to pivotal studies) Superior to sorafenib IMbrave 150) ANEX stopping the combination is in the first line NCIALES COMPA vacizumab mab mab s to the hospital Day administration ib (trial Pagi XO nation atezolizumab-be and treatment systems ARADAS WITH OTHERS Lenvat Lenvima® Oral 8/24 mg/ h (weight < 60 12/24mg/ h) (weight ≥ 60 Yes Arterial hypertension Diarrhoea Hyporexia Regimen not less than sorafenil (RECT test) 9 in 16 Women Patients ALTE 0kg) 0 in 10 Repeated intravenous injections and a peer-reviewed clinical study (NIVERC) 400 mg Orlistat or SIFARS SILARS Neutrogenous arterial hypersensitivity Syndrome Baseline characteristics of patients in the pivotal study IMbrav Comisi ve150 (15). Table 3. analysis by subgroup of surviv supplementary appendix IMbrave150. This is the first time that the European Parliament has voted in favour of the Commission's proposal for a regulation. I did.",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "",
        "start_page": 1,
        "end_page": 10,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 23,
        "merged": true
      }
    },
    {
      "text": "The number of deaths, n (%) 96 (28.6) 65 (39.4) 0.58 (0.42-0.79) a P< 0.001 Median of SG in months (IC 95%) NA 13.2 (10.4-NA) Atezolizumab- Sorafenib bevacizumab RARIC 95% (N=165) (N = 336) Rate of overall mean survival at 84, 80, 89-82, 72-75, 63-66, 95 (91%) (ti, 12, 19, 82% to 67, 6%) from randomisation to (n=336) death from any cause (SLP) was defined by the following criteria: (B) Secondary endpoints Efficacy analysis Parameters of efficacy Atezolizumab-bevacizumab Sorafen Secondary variables (N = 336) (N= 165) Objective response rate (percentage of patients with partial or complete response) Objective Response rate, % (IC) 95% by RECIST",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "REvalMed SNS Permanent member of the Committee of the Regions",
        "start_page": 13,
        "end_page": 15,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "0_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "1.1 Value of P< 0.001 Objective answer rate, (IC 95%) by MIST 33.2 (28,1-38,36) (P< 0.004-18,38) Duration of response (time from complete response or partial disease progression to deterioration or progression) Ratio of quality of life up to deteriorated condition (QLOR) 9.63 months (QC) Median time of life at risk (RICQ-NAC) 9.53 months (3.0-0.95) Median risk of life (QR) at the end of the test (QRC) 9.6 months (4.93-0.59) Risk of death in patients (QNOR) (6.5-NA) 3.6 (3.5-6 functional role subscale, months (CI 95%) Hazard Ratio (IC 95%) 0.62 (0.46-0.84) 1 Date of adoption of phase I of the report by GC REvalMed: 2 February 2022. Figure 2 The Ministry of Health estimates the number of cases of hepatocellular carcinoma in the Community as follows:",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "REvalMed SNS Permanent member of the Committee of the Regions",
        "start_page": 13,
        "end_page": 15,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": "0_1_0",
        "oversized_split": true,
        "merged": true
      }
    },
    {
      "text": "Row 2 contains: ' Name', 'Atezolizumab-bevacizumab', 'Lenvatinib', 'Sorafenib' Row 3 contains: \" Trade name', ' Tecentriq®-Avastin®', ' Lenvima®', \" Nexavar®' Row 4 contains: Hand-foot Diarrhoea Arterial hypertension' Row 8 contains: 'Utilization of resources', 'Need for Hospital Medical Day (HDM). Intrahospital administration', 'Outpatient regimen', 'Ambulatory regimen' Row 9 contains: \"Effectiveness (according to pivotal studies) \", 'Superior to sorafenib (IMbrave 150 trial) ', 'Not inferior to sorapenib (Reflect trial) ',' Superior to placebo (SHARP and Asia-Pacific trials) ' So\nad\nca\nTec\nPub\nww\n© NI cond\nor\ndv\narc\nchnol\nblishe\nww.nic\nICE 20 ditions#\nrafe\nvanc\ncin\nlogy ap ed: 6 S\nce.org. 024. All rig\n#notice-o\neni\nce\nnom\npprai\nSepte\n.uk/g\nghts res of-right\nib\ned\nm\nisa\nem\nguid\nser\nts). b fo d he\nma\nal guida mber 20\ndance/\nrved. Subj\nor t epa\nance\n/ta474\nject to No\ntr\nat\notice\nrea\ntoc\ne of rig\nating\ncellular\nghts",
      "metadata": {
        "doc_id": "IPT_50-2022-Tecentriq",
        "heading": "Table 1 on page 9",
        "start_page": 9,
        "end_page": 9,
        "created_date": "2022",
        "country": "ES",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/ES/IPT_50-2022-Tecentriq_cleaned.json",
        "split_index": 0,
        "merged": true
      }
    }
  ]
}